Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IAG933 |
Trade Name | |
Synonyms | IAG 933|IAG-933 |
Drug Descriptions |
IAG933 disrupts the interaction between yes-associated protein 1 (YAP) and the transcription factor TEAD, potentially leading to decreased YAP/TEAD-dependent gene expression and tumor growth inhibition (PMID: 38565920). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C185454 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Capmatinib + IAG933 | Capmatinib IAG933 | 0 | 0 |
Dabrafenib + IAG933 | Dabrafenib IAG933 | 1 | 0 |
Dabrafenib + IAG933 + LTT462 | Dabrafenib IAG933 LTT462 | 1 | 0 |
Dabrafenib + IAG933 + Trametinib | Dabrafenib IAG933 Trametinib | 1 | 0 |
IAG933 | IAG933 | 0 | 1 |
IAG933 + JDQ443 | IAG933 JDQ443 | 0 | 0 |
IAG933 + Lapatinib | IAG933 Lapatinib | 0 | 0 |
IAG933 + MRTX-1133 | IAG933 MRTX-1133 | 0 | 0 |
IAG933 + Osimertinib | IAG933 Osimertinib | 0 | 0 |
IAG933 + RMC-7977 | IAG933 RMC-7977 | 0 | 0 |